Human mitochondrial ribonuclease P (mtRNase P) is an essential three protein complex that catalyzes the 5' end maturation of mitochondrial precursor tRNAs (pre-tRNAs). MRPP3 (Mitochondrial RNase P Protein 3), a protein-only RNase P (PRORP), is the nuclease component of the mtRNase P complex and requires a two-protein S-adenosyl methionine (SAM)-dependent methyltransferase MRPP1/2 sub-complex to function. Dysfunction of mtRNase P is linked to several human mitochondrial diseases, such as mitochondrial myopathies. Despite its central role in mitochondrial RNA processing, little is known about how the protein subunits of mtRNase P function synergistically. Here we use purified mtRNase P to demonstrate that mtRNase P recognizes, cleaves, and methylates some, but not all, mitochondrial pre-tRNAs in vitro. Additionally, mtRNase P does not process all mitochondrial pre-tRNAs uniformly, suggesting the possibility that some pre-tRNAs require additional factors to be cleaved in vivo.
INTRODUCTION
Ribonuclease P (RNase P) catalyzes one of the first steps of tRNA maturation, the removal of the 5' leader sequences from precursor tRNAs (pre-tRNAs). There are two classes of evolutionarily distinct RNase Ps: RNA-based (ribozyme) and protein-based enzymes (Gobert et al. 2010; Holzmann et al. 2008; Taschner et al. 2012 ). RNase P is essential wherever pre-tRNAs are transcribed and is present in the nucleus, mitochondria and chloroplasts of cells. The proteinonly form of RNase P was first identified in human mitochondria and consists of three subunits: Mitochondrial RNase P Protein 1 (MRPP1, TRMT10C), Mitochondrial RNase P Protein 2 (MRPP2, 17β-hydroxysteroid dehydrogenase type 1, SDR5C1), and Mitochondrial RNase P Protein 3 (MRPP3 or human PRORP, catalytic nuclease subunit) (Holzmann et al. 2008; Vilardo et al. 2012 ).
Subsequently, Protein-Only RNase Ps (PRORPs) have been discovered in some land plants (e.g. Arabidopsis thaliana (Gobert et al. 2010; Gutmann, Gobert, and Giege 2012) ) and other unicellular Eukaryotic organisms (e.g. Trypanosoma bruceii ). It is noteworthy that in archaea and bacteria, 5' tRNA enzymes containing a similar catalytic domain to PRORPs were also recently identified (HARPs, Homologs of Aquifex RNase P). These enzymes were shown to be the smallest RNase P with independent 5' end pre-tRNA processing endonuclease activity (Nickel et al. 2017) . In contrast to human mtRNase P, PRORPs are stand-alone enzymes that do not require accessory proteins. Most studies of protein-based RNase Ps have focused on PRORPs because these enzymes are homologous to MRPP3 and provide a tractable system for study (Pinker et al. 2017; Gobert et al. 2013; Gutmann, Gobert, and Giege 2012; Gobert et al. 2010; Karasik et al. 2016; Howard et al. 2013; Howard et al. 2012; Howard et al. 2016; Klemm et al. 2016) . As a consequence, little is known about how the components of the metazoan mtRNase P complex function.
In mitochondria, RNAs are transcribed in polycistronic units. In each polycistronic unit, most protein-coding and rRNA transcripts are separated (or 'punctuated') by tRNAs. Therefore 5' end and 3' end tRNA processing is required for the processing of most key mitochondrial RNAs (Ojala, Montoya, and Attardi 1981) . 5' End cleavage by mtRNase P has been suggested to be the first step in the hierarchical tRNA processing in mitochondria (Sanchez et al. 2011; Reinhard, Sridhara, and Hallberg 2017; Rossmanith et al. 1995) . More than 50% of mitochondrial disease-causing mutations in the mitochondrial genome are found in tRNA genes (Abbott, Francklyn, and Robey-Bond 2014) . Since precursor tRNA processing is likely the first step in the mitochondrial tRNA maturation pathway, disabling this function leads to accumulation of mitochondrial precursor tRNAs along with unprocessed RNA transcripts (Sen et al. 2016; Rackham et al. 2016) .
Accumulation of unprocessed RNA in the mitochondria affects downstream processes such as mitochondrial ribosome assembly and translation with detrimental effects on mitochondrial function and viability. It is therefore predicted that mitochondrial RNA processing plays a role in mitochondrial diseases.
Consistent with this idea, mtRNase P dysfunction is linked to several mitochondrial diseases including maternally inherited essential hypertension (Wang et al. 2011) , mitochondrial myopathy (Bindoff et al. 1993; Rossmanith and Karwan 1998) , MELAS (Li and Guan 2010) , and HSD10-disease (Deutschmann et al. 2014; Chatfield et al. 2015) .
All three subunits of mtRNase P are strictly required in vivo; knockout of any component in flies leads to larval lethality (Sen et al. 2016 ). In addition, knockdown of MRPP1 and MRPP3 in human cell lines was shown to affect 5' end mitochondrial pre-tRNA processing and mature mitochondrial tRNA levels (Holzmann et al. 2008; Sanchez et al. 2011) . This further emphasizes that in general, processing activity of MRPP3 is dependent on other components of mtRNase P.
Similarly, knock-out of the MRPP3 gene in mice arrests embryogenesis at a very early stage (Rackham et al. 2016 ). Furthermore, mice containing a conditional knock-out of MRPP3 develop cardiomyopathy, show signs of mitochondrial dysfunction, and exhibit severe defects in 5' end RNA processing (Rackham et al. 2016 ). MRPP3 has also been shown to further influence tRNA modifications; for example a missense mutation in MRPP3 was identified as an important factor responsible for differences in mitochondrial tRNA methylation patterns (Hodgkinson et al. 2014 ). Thus, correct mtRNase P function is likely to be essential for human health.
Little is known about the structure and function of the mtRNase P complex;
there are no structures or structural models and limited mechanistic and biochemical information available, although structures of truncated MRPP3 have been solved Howard et al. 2012; Reinhard, Sridhara, and Hallberg 2015; Li et al. 2015) . As such, the role of the interaction between MRPP3 and the MRPP1/2 sub-complex in enhancing substrate binding and catalysis is a key question in the function of human mtRNase P (Holzmann et al. 2008 ). The MRPP1/2 sub-complex has been predicted to methylate the N1 of adenine or guanine residues at the 9 th position of 19 mitochondrial tRNAs (Vilardo et al. 2012) .
MRPP1 is the S-adenosyl-methionine (SAM) dependent methyltransferase subunit in the MRPP1/2 sub-complex, and MRPP2 likely acts as a scaffold protein (Vilardo et al. 2012 ).
Here we investigate how MRPP1, MRPP2, and MRPP3 work together to recognize and cleave pre-tRNA substrates. Our work with recombinant mtRNase P reveals that the complex can specifically bind, process and methylate several human mitochondrial pre-tRNAs which are not recognized and processed by singlesubunit plant PRORPs. Additionally, a subset of human mitochondrial pre-tRNA substrates are not processed efficiently by the recombinant mtRNase P complex suggesting that additional components or modifications may be required to facilitate cleavage of these substrates. We further demonstrate that the MRPP1 cofactor SAM enhances the ability of the mtRNase P complex to bind and cleave some substrates. Overall, our studies deepen insight into how the components of mtRNase P act synergistically to bind, process and methylate human mitochondrial pre-tRNAs.
RESULTS

mtRNase P binds mitochondrial precursor-tRNAs non-uniformly
Although the human mtRNase P complex was discovered almost a decade ago, it is largely unknown how it recognizes and binds its mitochondrial substrates (Holzmann et al. 2008) . The pool of native mtRNase P substrates is diverse; in human mitochondria there are four subtypes of tRNAs (Type 0-III). The (mt)tRNAs belonging to types I, II, and III all differ from the canonical cloverleaf secondary structure of nuclear tRNAs (Helm et al. 2000; Suzuki, Nagao, and Suzuki 2011) .
We selected six mitochondrial pre-tRNA ((mt)pre-tRNAs) substrates to study representatives of all four classes including a substrate ((mt)pre-tRNA Ser(AGY) ) that human mtRNase P is not expected process in vivo (Rossmanith 1997) (Figure 1 ).
The exact lengths of 5' and 3' flanking ends of mtRNase P substrates have not yet been established; therefore, we used our knowledge of A. thaliana single subunit PRORP enzymes that are homologous to MRPP3 to design the 5' and 3' ends of our (mt)pre-tRNA substrates. PRORPs preferentially bind substrates with short (< 5-8 nucleotide) 5' leaders and do not bind the 3' trailer of pre-tRNAs Howard et al. 2016; Brillante et al. 2016) . Thus, the (mt)pre-tRNA substrates studied here possess 6-7 nucleotide long 5' leader sequences and lack mature 3' CCA ends (Figure 1 ).
To determine how each component of the mtRNase P complex interacts with (mt)pre-tRNAs we measured the binding constant (KD or KD,app) for the mtRNaseP complex components (MRPP1/2 sub-complex and MRPP3) and six (mt)pre-tRNAs of interest using fluorescence anisotropy binding assay. We find that the isolated mtRNase P components generally do not associate tightly with the selected substrates (Table 1, Figure 2A and B). MRPP3 alone binds all of the (mt)pre-tRNAs substrates weakly with KD values > 4 µM (Table 1 and Figure 2A ).
The MRPP1/2 sub-complex similarly binds most substrates weakly (KD,app > 2 µM) with the exception of (mt)pre-tRNA Ile and (mt)pre-tRNASer UCN , which it binds more tightly (KD,app values of 104 ± 24 nM and 730 ± 196 nM, respectively) (Table 1, Figure 2B ).
We next sought to establish how the fully-reconstituted mtRNase P complex (MRPP1/2:3) interacts with (mt)pre-tRNA substrates. For these assays, first we incubated pre-folded (mt)pre-tRNAs with 150 nM MRPP1/2. After MRPP1/2 and pre-tRNA binding reached equilibrium (5 minutes) we added varying concentrations of MRPP3 (0-10 M, Figure 2C and D) and measured additional changes in fluorescence anisotropy. In general, we find that the presence of the MRPP1/2 sub-complex enhances (mt)pre-tRNA binding by 30 to 330-fold over binding to MRPP3 alone (Table 1) . However, these enhancements are not uniform.
The substrates fall into two categories: those that bind the complex somewhat tighter than MRPP3 alone (3-5 fold: (mt)pre-tRNA Val , (mt)pre-tRNASer UCN , (mt)pre-tRNA Ser(AGY) ) and those that bind the complex significantly tighter (30-330 fold:
(mt)pre-tRNA Leu , (mt)pre-tRNA Ile , (mt)pre-tRNA Met ). As anticipated the substrate that binds the weakest is (mt)pre-tRNA Ser(AGY) . Notably, the mtRNase P complex exhibits the tightest KD,app (13.5 ± 2.3 nM) for (mt)pre-tRNA Ile . These results indicate that while a subset of human (mt)pre-tRNAs are recognized with high affinity by mtRNase P (KD,app values are in the nanomolar range), there are other (mt)pre-tRNAs that have weaker affinity (KD,app values in the micromolar range) and may require additional factors or modifications to bind tightly to mtRNase P.
To compare substrate selectivity of human mtRNase P complex with single component PRORP1 and 2 enzymes we tested the ability of A. thaliana PRORP1 and PRORP2 to bind our six human (mt)pre-tRNA substrates (Table 1 and Supplemental Table 2 ). We find that only (mt)pre-tRNA Ser(UCN) binds to PRORP1 and 2 with a comparable KD value (60-120 nM) to that of their native A. thaliana substrates. All other (mt)pre-tRNAs were bound at least 7-fold less tightly (KD = 880 nM to > 10 µM, Supplemental Table 2 ). Thus, mtRNase P uses strategies or interactions for recognizing its substrates that are different from the singlecomponent PRORP1 and 2 enzymes.
mtRNase P exhibits 5' end processing of tightly bound (mt)pre-tRNAs
To further understand mtRNaseP substrate selectivity we measured single turnover cleavage rate constants for the six (mt)pre-tRNAs discussed above ( Figure 1 ). Previously, we used fluorescence polarization-based multiple turnover assays for monitoring pre-tRNA 5' end cleavage by RNA-based and singlecomponent protein only RNase Ps (A. thaliana PRORPs) (Liu, Chen, and Fierke 2014; Howard et al. 2016) . Here, we adapted this method to monitor the cleavage of 5'-fluorescein labeled (mt)pre-tRNAs by the fully-reconstituted human mtRNase P complex in single turnover cleavage assays. We measured the single turnover rate constants (kobs) and K1/2 MRPP3 values for mtRNaseP using limiting substrate (20 nM fluorescent pre-tRNA) and a range (100 nM-2 µM) of MRPP3 concentrations at 28 ˚C while MRPP1/2 concentration was maintained constant at near saturating levels (500 nM) ( Figure 3A and B, Supplemental Figure 3B ).
All of the (mt)pre-tRNAs that bind with relatively high affinity to the mtRNase P complex ((mt)pre-tRNA Leu , (mt)pre-tRNA Ile , (mt)pre-tRNA Met ) have K1/2 MRPP3 values, ranging from ~ 390 nM to 930 nM, greater than the measured binding affinities (KD,app values in CaCl2), suggesting that K1/2 MRPP3 does not reflect a thermodynamic binding equilibrium under single turnover conditions. The KD,app values that we report were measured in CaCl2 under conditions that permit binding, but do not promote substrate cleavage. Though unlikely, we cannot rule out the possibility these conditions do not entirely reflect binding of substrates to mtRNase P in MgCl2, when cleavage can occur. The kobs values for these substrates range between 0.4 -0.8 min -1 ( Figure 3C , Table 1 ) and correlate well with rate constants previously measured for single-subunit PRORPs cleaving their native substrates Brillante et al. 2016; Howard et al. 2016) . In contrast, (mt)pre-tRNAs that have low affinities for mtRNase P ((mt)pre-tRNA Val , (mt)pre-tRNASer UCN , (mt)pre-tRNA Ser(AGY) )) exhibit ~ 100-fold lower single turnover activity (kobs ~0.06 min -1 ) ( Figure 3C and Table 1 ); the cleavage of these substrates was so slow that we were unable to accurately measure K1/2 MRPP3 values. We also considered the possibility that the length of the pre-tRNA 5' leader or 3' trailer sequences impacts cleavage by mtRNase P (Supplemental Figure 4 ). To test this possibility, we measured the rate constant for mtRNase P cleavage of substrates with long length 5' leaders and 3' trailers. We found that the length of 3' and 5' sequences does not significantly alter the ability of mtRNase P to cleave (mt)pre-tRNA Ser(UCN) and (mt)tRNA Ile constructs. Our findings that the same substrates that bind poorly are also cleaved inefficiently by mtRNase P in single turnover assays (where binding is not the rate-limiting step) suggests that these may not be oriented properly in the bound complex.
As mentioned earlier, we find that most human mitochondrial pre-tRNAs are not bound tightly by A. thaliana PRORP1 and PRORP2, therefore we sought to address whether cleavage catalyzed by PRORP1 and 2, as measured by single turnover reaction rates, is also slow for these substrates. In good agreement with our binding data, PRORP1 and PRORP2 processed most human (mt)pre-tRNAs with single turnover rates more than 10-fold slower than that of mtRNase P, except for pre-tRNA SerUCN (Figure 3D , Supplemental Table 2 ). Pre-tRNA SerUCN is not processed efficiently by the mtRNase P but is cleaved by PRORP1 and 2 with single turnover rate constants comparable to that of their native substrates (~0.3-0.7 min -1 ) ( Figure 3D , Supplemental Table 2 ). Together with our binding data this suggests that human mitochondrial pre-tRNAs are recognized differently by A. thaliana PRORPs and human mtRNase P.
MRPP3 can enhance the methylation activity of the MRPP1/2 sub-complex
The MRPP1/2 sub-complex was previously shown to methylate in vitro transcribed human (mt)pre-tRNAs (Vilardo et al. 2012 ). Here we measured the single turnover rate constants for MRPP1/2 catalyzing methylation of (mt)pre-tRNAs containing potential m1A9/m1G9 modification sites ((mt)pre-tRNA Ile , (mt)pre-tRNA Leu and (mt)pre-tRNA Val ) (Figure 1 , Figure 4A ). To determine the rate of methylation, we developed fluorescence primer extension assays for the mtRNase P complex (described in materials and methods, Figure 4B ). Additionally, we also assessed if the presence of MRPP3 modulates MRPP1/2 methylation activity. Our data demonstrate that the single turnover rate constants (kobs,meth) for methylation of (mt)pre-tRNA Ile are 0.13 ± 0.02 min -1 catalyzed by near saturating MRPP1/2 concentrations and that the addition of MRPP3 does not alter the kobs,meth value for this substrate ( Figure 4C and F,). In comparison, methylation rates for (mt)pre-tRNA Leu (UUR) are a modest 2-fold higher when MRPP3 is present ( Figure   4D and F) (0.08 ± 0.01 min -1 in the absence and 0.15 ± 0.03 min -1 in the presence of MRPP3). MRPP1/2 also catalyzed methylation of (mt)-pre-tRNA Val , however, the rates are significantly slower (kobs,meth < 0.005 min -1 ) compared to the other two pre-tRNA substrates suggesting that there are differences in how MRPP1/2 binds and methylates each pre-tRNA substrate ( Figure 4E ).
SAM is required for mtRNase P to efficiently bind and process some human mitochondrial pre-tRNAs
As discussed above, we found that some human mitochondrial pre-tRNAs are not efficient substrates for the reconstituted mtRNase P complex in vitro.
However, in vivo RNA sequencing experiments suggest that most mitochondrial tRNAs are processed by the mtRNase P complex, including (mt)pre-tRNA Val and (mt)pre-tRNASer UCN (Rackham et al. 2016) . This led us to consider whether some substrates, such as (mt)pre-tRNA Val and (mt)pre-tRNASer UCN , might require either additional modification steps prior to mtRNase P cleavage, or additional co-factors, such as a protein or small molecule.
As a first step, we investigated if the presence of the methyl donor, SAM, affects the binding affinity of the six (mt)pre-tRNAs used in this study (Figure 1 .)
We added a high concentration of SAM (25 µM) to our fluorescence anisotropy binding assays and measured (mt)pre-tRNA binding affinities for the MRPP1/2 and mtRNase P complexes (Supplemental Table 3 and 4). We find that the presence of SAM enhances the binding affinity of (mt)pre-tRNA Val for both the MRPP1/2 and the mtRNase P complexes ≥ 15-fold ( Figure 5A and B, Supplemental Table 3 ).
Next, we determined if this effect is due to the presence of SAM or methylation of the m1A9 site of (mt)pre-tRNA Val . We first measured the (mt)pre-tRNA Val binding affinities for MRPP1/2 and mtRNase P in the presence of the co-factor product of methyl-transfer, SAH, demonstrating an at least ~3 but up to 6-fold decrease in KD,app ( Figure 5A and B, Supplemental Table 3 ). To further examine whether methylation is required for the increased binding affinity, we measured the KD,app of MRPP1/2 and mtRNase P for a methylation site mutant of (mt)pre-tRNA Val ((mt)pre-tRNA Val/C9 ). The addition of either SAM or SAH enhances the binding affinity of the (mt)pre-tRNA Val/C9 mutant to the same extent as for the wild-type substrate ( Figure 5A and B, Supplemental Table 3 ). This suggests that the presence of SAM, but not methylation, is important for (mt)pre-tRNA Val substrate recognition.
In addition, we find that (mt)pre-tRNA Leu(UUR) binds the MRPP1/2 complex ~4-5-fold tighter in the presence of SAM and SAH ( Figure 5A ), similar to (mt)pre-tRNA Val . However, binding affinities for mtRNase P or MRPP1/2 sub-complex for the remaining four substrates are not significantly altered in the presence of SAM (Supplemental Table 4 ).
We next investigated if the presence of SAM and SAH impact the ability of mtRNase P to cleave the 5' end of (mt)pre-tRNAs. We find that the single turnover rate constants for the 5' end cleavage of (mt)pre-tRNA Val by mtRNase P is increased by 3 to 7-fold in the presence of SAH or SAM, respectively ( Figure 5C , Supplemental Table 3 ). Moreover, the single turnover cleavage rates for (mt)pre-tRNA Val/C9 catalyzed by mtRNase P exhibit a similar pattern ( Figure 5C , Supplemental Table 3 ). Despite this rate enhancement, it is noteworthy that the rate constant for the processing of (mt)pre-tRNA Val in the presence of SAM is approximately 3 times slower than for any of the other investigated (mt)pre-tRNAs without the presence of SAM (Table 1 and Supplemental Table 3 ). Addition of SAM or SAH did not enhance the single-turnover rate constants for any of the other (mt)pre-tRNAs that we investigated (Supplemental Table 4 ). Our results demonstrate that SAM increases the binding efficiency and 5' end processing catalyzed by mtRNase P for a subset of (mt)pre-tRNAs.
DISCUSSION
Given the essential nature of human mtRNase P and its direct link to disease it is important to understand how this protein complex functions. Despite its importance, it is mostly unclear how mtRNase P binds and processes its (mt)pre-tRNA substrates. Significantly, how the three components of the mtRNase P interact remains a major question. Here we directly address these critical knowledge gaps by investigating how human mtRNase P binds, cleaves and methylates representative human mitochondrial pre-tRNAs. Our data demonstrate that there is extensive interplay between the mtRNase P components (MRPP1/2/3 and the MRPP1 cofactor SAM) required to recognize, process and methylate human mitochondrial pre-tRNAs. We found that mtRNase P exhibits distinct modes of substrate recognition for individual human mitochondrial pre-tRNAs, in contrast to the homologous single protein component PRORPs that bind and cleave their native substrates more uniformly .
The mitochondrial genome encodes 22 tRNAs that fall into four different types 2016)) (Watanabe, Suematsu, and Ohtsuki 2014) . In our study, we investigated the processing of pre-tRNAs representative of all four categories of mitochondrial pre-tRNAs: (mt)pre-tRNA Leu (type 0), (mt)pre-tRNA Ser(UCN) (type I), (mt)pre-tRNA Ile (type II), (mt)pre-tRNA Met (type II), (mt)pre-tRNA Val (type II) and (mt)pre-tRNA Ser(AGY) (type III). These pre-tRNAs are of significant interest because all are hot spots for mutations responsible for a plethora of human mitochondrial diseases (Wortmann et al. 2012; Rossmanith and Karwan 1998; Yan, Zareen, and Levinger 2006; Wang et al. 2011) . Additionally, (mt)pre-tRNA Val is of note because it is transcribed between the two mitochondrial rRNAs and is proposed to play an unusual and noncanonical structural role as part of the human mitochondrial ribosome (Amunts et al. 2015; Greber et al. 2015) .
Using our selected substrates, we determined both how individual components of the mtRNase P (MRPP3 and MRPP1/2) and the mtRNase P complex bind type 0-III (mt)pre-tRNAs. We find that MRPP3 and MRPP1/2 individually bind most (mt)pre-tRNAs with low affinity (KD,app values in µM range). However, for (mt)pre-tRNA Leu , (mt)pre-tRNA Ile , (mt)pre-tRNA Met binding affinities are significantly (KD,app values in nM range) enhanced when the entire complex is present. This suggests that the different components in the mtRNase complex depend on each other to recognize some substrates. The substrates that bind weakly to mtRNase P include a variety of types (type I (mt)pre-tRNASer (UCN) , type II (mt)pre-tRNA Val , and type III (mt)pre-tRNASer (AGY) ). The inability of the complex to bind (mt)pre-tRNA Ser (AGY) was not surprising because this substrate lacks the entire D-loop and stem ( Figure   1 ) and is not predicted to be a substrate of mtRNase P in vivo (Rossmanith 1997 ).
However, the weaker binding of (mt)pre-tRNA Val and (mt)pre-tRNASer (UCN) was unexpected since there are no obvious structural or sequence differences that explain the low affinity with mtRNase P.
The efficiency of mtRNase P catalyzing the 5' end cleavage of particular (mt)pre-tRNAs follows the same pattern as substrate binding; (mt)pre-RNAs that associate tightly are processed 8-20 times faster (single turnover kobs=0.4 -0.8 min -1 ) than substrates that bind weakly (kobs ~0.06 min -1 ). The correlation between weak binding and slow cleavage rates at saturating enzyme concentrations suggests that these pre-tRNA substrates do not bind optimally for cleavage.
Notably, all (mt)pre-tRNAs that are recognized and processed efficiently by human mtRNase P are type 0 or II substrates. However, not all type II pre-tRNAs are efficiently processed by mtRNase P, such as pre-tRNA Val , suggesting that the 'type' of (mt)pre-tRNA structure is insufficient to predict how mtRNase P will recognize any given substrate. Our data indicate that the recombinant mtRNase P does not recognize all substrates equally, leading us to posit that additional factors beyond MRPP1/2 and MRPP3 may be required to ensure that all (mt)pre-tRNAs are efficiently processed in cells.
To gain further insight into the interplay between 5' end pre-tRNA processing and methylation activities of mtRNase P, we measured the single turnover methylation rates of MRPP1/2 in the presence and absence of MRPP3. These assays were performed using the (mt)pre-tRNAs that possess m1A9/m1G9 methylation sites ((mt)pre-tRNA Ile , (mt)pre-tRNA Leu , (mt)pre-tRNA Val ). We find that single turnover rates for methylation were at least 5 times slower than 5' end processing (Table 1 and Figure 4 , e.g. kobs,cleav ~ 0.8 min -1 and kobs, meth ~0.13 min -1 for (mt)pre-tRNAIle), suggesting that cleavage may occur prior to methylation.
This finding is in agreement with previous studies that assessed (mt)pre-tRNA Ile methylation catalyzed by mtRNase P (Vilardo and Rossmanith 2015) . Recent work indicated that 5' end processing and methylation of (mt)pre-tRNA Ile catalyzed by mtRNase P are carried out by the components of mtRNase P independently, and do not affect one another, further suggesting the structural, but not catalytical role of MRPP1/2 in 5' end processing (Vilardo et al. 2012; Vilardo and Rossmanith 2015) . While our results with (mt)pre-tRNA Ile and (mt)pre-tRNA Val corroborate this suggestion, we find that the presence of MRPP3 modestly increases the rate constant for methylation of (mt)pre-tRNA Leu by MRPP1/2. This implies that the two functions of mtRNase P are not entirely de-coupled, and that there may be cooperation between the 5' end tRNA processing and methyltransferase functions of mtRNase P for some substrates.
Based on in vivo experiments (Rackham et al. 2016; Holzmann et al. 2008 ), (mt)pre-tRNA Val is predicted to be a substrate of mtRNase P. However, we show that this substrate is not recognized and processed efficiently by recombinant mtRNase P in vitro. It has been previously demonstrated that (mt)tRNA Lys requires methylation at the 9 th base in order to fully adopt the clover-leaf secondary structure (Helm et al. 1998; Sissler et al. 2004; Motorin and Helm 2010) . This result suggested that methylation of (mt)pre-tRNA Val at the 9 th position might be necessary for this substrate to fold (and subsequently be processed by mtRNase P), akin to (mt)tRNA Lys . Consistent with this model, we observed that the binding and cleavage of (mt)pre-tRNA Val by mtRNase P is significantly enhanced by the addition of SAM ( Figure 5 ). However, similar effects are observed upon either addition of SAH, a SAM analogue that does not function as a cofactor for methylation catalyzed by MRPP1/2, or using the A to C9 methylation site mutant of (mt)pre-tRNA Val (Figure 5) . These results suggest that the SAM-mediated effect on (mt)pre-tRNA Leu and (mt)pre-tRNA Val binding affinity and processing by mtRNase P is linked to cofactor binding to MRPP1/2 rather than pre-tRNA Furthermore, in the presence of SAM, a bifunctional restriction enzyme harboring a methyltransferase domain, RM.BpuSI, had increased processing activity without significant methylation activity (Sarrade-Loucheur, Xu, and Chan 2013), similar to mtRNase P acting on (mt)pre-tRNA Val . Additionally, a recent study showed an increase in melting temperature for MRPP1 in the presence of SAM indicating a stabilizing effect of the co-factor (Oerum et al. 2018) . Based on our data, we propose that the presence of SAM bound to MRPP1 enhances the ability of MRPP1 to bind some pre-tRNA substrates. Our finding also agrees well with the previous observation (Vilardo and Rossmanith 2015) that MRPP1/2 mainly provides structural support for MRPP3.
While we observe that SAM is a key factor for recognition of (mt)pre-tRNA Val by MRPP1/2 and subsequently MRPP3, (mt)pre-tRNA Ser(UCN) is bound to MRPP1/2 efficiently (Table 1) but to mtRNase P poorly. Therefore one possibility is that the recognition of the MRPP1/2-(mt)pre-tRNA Ser(UCN) complex by MRPP3 requires an unidentified mitochondrial factor; however, this needs further testing.
In non-metazoan eukaryotes, the MRPP3-homologous PRORP enzymes are stand-alone proteins able to cleave a wide variety of substrates from different organisms (Gobert et al. 2010; Karasik et al. 2016; Howard, Klemm, and Fierke 2015) . To gain insight into potential differences as to how single-protein PRORPs and complex-forming MRPP3 enzymes select and cleave their substrates we assessed the ability of A. thaliana PRORP1 and PRORP2 to recognize and process human (mt)pre-tRNAs. Our results suggest that complex-forming protein only RNase Ps recognize their substrates differently than single enzyme PRORPs.
Since A. thaliana PRORPs recognize the L-shaped tertiary structure of pre-tRNAs (Klemm et al. 2017; Pinker et al. 2017; Imai et al. 2014; Gobert et al. 2013) , we propose that mtRNase P may interact with pre-tRNAs by recognizing local structural elements or specific bases within the (mt)pre-tRNAs. Some human mitochondrial tRNAs are known to adopt alternate secondary structures (Lorenz, Lunse, and Morl 2017) and mtRNase P may have conformed to be able to recognize these non-canonical structures.
Taken together, our in vitro studies demonstrate that different human mitochondrial pre-tRNAs interact distinctly with mtRNase P and this recognition mode is potentially an important determinant for 5' tRNA processing. Additionally, we found that some substrates are not efficiently bound and processed by mtRNase P suggesting a role of other factors in mitochondrial 5'end tRNA processing. In line with this, we found that SAM, the cofactor of MRPP1, can enhance substrate recognition and 5' processing by mtRNAse P. Our data reveal that single subunit PRORPs and human mitochondrial RNase P have distinct modes of pre-tRNA recognition. In addition, our data provide the first evidence that there is an interplay between the 5' end (mt)pre-tRNA processing and methylation functions of mtRNase P. Together, this work builds on the understanding of the role of MRPP1/2 developed previously (Vilardo et al. 2012 ) and provides an expanded framework for how the different components of mtRNase P work together to bind, process and methylate mitochondrial pre-tRNAs.
MATERIALS AND METHODS
In vitro transcription and 5' end labeling of pre-tRNAs. Pre-tRNAs were prepared as previously described Howard et al. 2012) . Briefly, to label the 5' end of tRNA with fluorescein, we incubated ~200 µL of 5' GMPS (guanosine-5-monophosphorotioate) labeled in vitro transcribed pre-tRNA overnight (in Tris-EDTA buffer of pH 7.2) with 20 µl 45 mM fluorescein (final concentration ~4 mM) at 37 ˚C and the reaction was purified on a 12% ureapolyacrylamide gel. After gel purification, pre-tRNAs were ethanol precipitated and the resulting pellet was re-suspended in RNase free H2O. The concentrations of total and labeled pre-tRNA were measured from absorbance readings at 260 nm using a Nanodrop (Thermo Scientific) spectrophotometer using the following extinction coefficients: 909,100 cm -1 mol -1 for (mt)pre-tRNA Ile7:0 , 927,300 cm -1 mol -1 for (mt)pre-tRNA Leu6:0 , 848,600 cm -1 mol -1 for (mt)pre-tRNA Val7:0 , 838,200 cm -1 mol -1 for (mt)pre-tRNA Met6:0 , 848,600 cm -1 mol -1 for (mt)pre-tRNA Ser(UCN)7:0 , 737,900 cm -1 mol -1 for (mt)pre-tRNA Ser(AGY)7:0 .
Protein expression and purification. His6-Δ95 MRPP3 was cloned into a pMCSG7 vector and transformed into E. coli BL21(DE3) cells. Transformed bacteria were grown overnight (5 mL LB media, 100 µg/ml ampicillin, 37 ˚C (220 rpm)), and used to inoculate 500 mL of TB media with 50 µg/ml ampicillin. Cultures (1:20 protein:TEV protease ratio) to remove the His tag. His6-TEV protease was removed by running the sample through a HisTrap nickel column. Δ95 MRPP3 was then dialyzed against 20 mM MOPS pH 7.8, 1 mM TCEP, 150 mM NaCl and 2 mM EDTA overnight at 4 ˚C to remove any possible metal contamination, followed by buffer exchange with 20 mM MOPS pH 7.8, 1 mM TCEP and 150 mM NaCl using a desalting column (BioRad). Protein concentration was measured using a Nano spectrophotometer (Thermo scientific) with molecular weight and extinction coefficient values of 56.4 kDa and 82500 cm -1 mol -1 , respectively.
Full length MRPP2 and His6-Δ39 MRPP1 were cloned and co-expressed as described (Liu 2013) . The MRPP1 N-terminal deletion corresponds to the predicted mitochondrial targeting sequence. Initial steps for protein expression and purification, including nickel column purification, histidine tag and TEV removal are identical to those detailed above for Δ95MRPP3, with the following exceptions: the antibiotic used was streptomycin (50 µg/ml) and 10% glycerol was added to each Therefore, protein concentration was measured based on molecular weight and extinction coefficient values of 149 kDa and 79520 cm -1 mol -1 . A. thaliana PRORP1 and PRORP2 were expressed and purified from E. coli as previously described (Howard et al. 2012; Karasik et al. 2016) . MRPP3 in cleavage reaction buffer were added to 20 nM fluorescently labeled pre-tRNA. Changes in fluorescence polarization were followed at 28 ˚C using a ClarioStar plate reader (BMG LabTech). In these assays, we found that the changes in anisotropy observed in the presence of the MRPP1/2 sub-complex and MRPP3 in isolation are small (<1-10%) relative to the significant changes in anisotropy due to cleavage catalyzed by the mtRNase P complex and as such do not impact the rate constants that we measure ( Figure 3A) . The results of our fluorescence polarization kinetic assays were verified using traditional gel-based cleavage assays (Supplemental Figure 1) Furthermore, to ensure that N-terminal truncation of Δ95 MRPP3 did not affect single turnover activity of mtRNase P we also reconstituted mtRNase P with Δ45 MRPP3 lacking only the mitochondrial targeting sequence. We found nearly identical single turnover observed cleavage rates for both complexes (Supplemental Table 1 ). Annealing primer sequences were designed against the anticodon loop for (mt)pre-tRNA Ile , (mt)pre-tRNA Leu , (mt)pre-tRNA Val and (mt)pre-tRNA Met (6-FAM-CTATTATTTACTCTATC; 6-FAM-CCTCTGACTGTAAAG; 6-FAM-CCTAAGTGTAAGTTGGG; and 6-FAM-CGGGGTATGGGCCCG, respectively).
5' end
Next, annealing reaction mixtures were incubated at 95˚C for 3 minutes followed by cool down to 37˚C for 10-15 minutes. As a control, previously folded pre-tRNA was used that was not incubated with the enzymes. 
